These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26376080)

  • 1. Role of pharmacotherapy in cardiac ion channelopathies.
    El-Sherif N; Boutjdir M
    Pharmacol Ther; 2015 Nov; 155():132-42. PubMed ID: 26376080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of pharmacotherapy in cardiac ion channelopathies.
    El-Sherif N; Pedalino R; Himel H
    Curr Vasc Pharmacol; 2009 Jul; 7(3):358-66. PubMed ID: 19601860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome.
    Kaufman ES
    Heart Rhythm; 2009 Aug; 6(8 Suppl):S51-5. PubMed ID: 19631908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmogenic hereditary syndromes: Brugada Syndrome, long QT syndrome, short QT syndrome and CPVT.
    Schimpf R; Veltmann C; Wolpert C; Borggrefe M
    Minerva Cardioangiol; 2010 Dec; 58(6):623-36. PubMed ID: 21135804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic and clinical features of cardiac channelopathies.
    Roberts JD; Gollob MH
    Future Cardiol; 2010 Jul; 6(4):491-506. PubMed ID: 20608822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Asymptomatic channelopathies : Risk stratification and primary prophylaxis].
    Aweimer A; Mügge A; Akin I; El-Battrawy I
    Herzschrittmacherther Elektrophysiol; 2023 Jun; 34(2):101-108. PubMed ID: 37103573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac channelopathies: genetic and molecular mechanisms.
    Abriel H; Zaklyazminskaya EV
    Gene; 2013 Mar; 517(1):1-11. PubMed ID: 23266818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Channelopathies, genetic testing and risk stratification.
    Wilde AAM; Amin A
    Int J Cardiol; 2017 Jun; 237():53-55. PubMed ID: 28343764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sudden death and ion channel disease: pathophysiology and implications for management.
    Bastiaenen R; Behr ER
    Heart; 2011 Sep; 97(17):1365-72. PubMed ID: 21685181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ion Channel Disorders and Sudden Cardiac Death.
    Garcia-Elias A; Benito B
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic basis of malignant channelopathies and ventricular fibrillation in the structurally normal heart.
    Hofman N; van Lochem LT; Wilde AA
    Future Cardiol; 2010 May; 6(3):395-408. PubMed ID: 20462344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular tachycardia in the absence of structural heart disease.
    Srivathsan K; Lester SJ; Appleton CP; Scott LR; Munger TM
    Indian Pacing Electrophysiol J; 2005 Apr; 5(2):106-21. PubMed ID: 16943951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Postmortem genetic testing in sudden cardiac death due to ion channelopathies].
    Guan DW; Zhao R
    Fa Yi Xue Za Zhi; 2010 Apr; 26(2):120-7. PubMed ID: 20653139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects.
    Skinner JR; Winbo A; Abrams D; Vohra J; Wilde AA
    Heart Lung Circ; 2019 Jan; 28(1):22-30. PubMed ID: 30389366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies.
    Hsiao PY; Tien HC; Lo CP; Juang JM; Wang YH; Sung RJ
    Appl Clin Genet; 2013; 6():1-13. PubMed ID: 23837003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes.
    Antzelevitch C; Oliva A
    J Intern Med; 2006 Jan; 259(1):48-58. PubMed ID: 16336513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological approach to the treatment of long and short QT syndromes.
    Patel C; Antzelevitch C
    Pharmacol Ther; 2008 Apr; 118(1):138-51. PubMed ID: 18378319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation.
    Napolitano C; Bloise R; Monteforte N; Priori SG
    Circulation; 2012 Apr; 125(16):2027-34. PubMed ID: 22529064
    [No Abstract]   [Full Text] [Related]  

  • 19. Sudden cardiac death in Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT).
    Singh M; Morin DP; Link MS
    Prog Cardiovasc Dis; 2019; 62(3):227-234. PubMed ID: 31078562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Syncopes and channelopathies].
    Müller-Leisse J; Zormpas C; König T; Duncker D; Veltmann C
    Herzschrittmacherther Elektrophysiol; 2018 Jun; 29(2):171-177. PubMed ID: 29766267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.